Primary Membranous Nephropathy
29
16
21
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 29 trials
100.0%
+13.4% vs benchmark
28%
8 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (29)
Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy
A Phase I Study of YK012 in Primary Membranous Nephropathy
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)
REmission in Membranous Nephropathy International Trial (REMIT)
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy